The European Lead Factory is funded by the Innovative Medicines Initiative (IMI) Joint Undertaking, and by the IMI2 Joint Undertaking under ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The Joint Undertaking receives support from the EU’s Horizon 2020 research and innovation programme, and EFPIA and the Medicines for Malaria Venture (MMV). The 8 pharmaceutical partners provide in-kind contributions. The European Lead Factory is governed by the Project Management Board and the Project General Assembly. Lygature is the project coordinator and Bayer the project leader.